Stock SLNO SOLENO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Soleno Therapeutics, Inc.

Equities

SLNO

US8342033094

Real-time Estimate Cboe BZX
Other stock markets
 10:58:24 2024-06-10 am EDT 		5-day change 1st Jan Change
47.08 USD +3.34% Intraday chart for Soleno Therapeutics, Inc. +10.05% +16.53%
Jun. 06 Transcript : Soleno Therapeutics, Inc. - Shareholder/Analyst Call
Jun. 04 Soleno Therapeutics to Join Russell 3000 Index MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Soleno Therapeutics, Inc. - Shareholder/Analyst Call
Soleno Therapeutics : June 2024 Corporate Presentation
PU
Soleno Therapeutics to Join Russell 3000 Index
MT
Soleno Therapeutics Set to Join Russell 3000® Index
AQ
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
AQ
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
CI
Soleno Therapeutics to Participate in Upcoming Investor Conferences
AQ
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
AQ
Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating
MT
Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target
MT
Soleno Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
AQ
Soleno Therapeutics Prices $138 Million Stock Offering
MT
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
AQ
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
AQ
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome
AQ
Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to Natural History of Prader-Willi Syndrome
CI
Soleno Therapeutics' Shares Jump After FDA Grants Breakthrough Designation for Prader-Willi Syndrome Treatment
MT
Soleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide Choline
DJ
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SLNO Stock
  4. News Soleno Therapeutics, Inc.